Codexis is a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, and the question for the next twelve months is whether the company can industrialize the ECO Synthesis Manufacturing Platform and convert the platform from research and development stage into commercial manufacturing relationships and revenue. The Q2 2026 print was the cleanest test yet of that thesis, and the cleanest signal is that CEO Alison Moore, PhD, used the TIDES US annual meeting in May 2026 to demonstrate that the ECO Synthesis Manufacturing Platform enables enzyme-driven stereoisomer control of siRNA, a manufacturing capability that did not previously exist at this scale. The combination of the $14.9 million of Q2 2026 total revenue, the 73 percent Q2 2026 product gross margin, the $11.7 million of Q2 2026 R&D expenses down from $13.8 million in Q2 2025, the $10.9 million of Q2 2026 SG&A expenses down from $12.3 million in Q2 2025, the $12.0 million of Q2 2026 net loss versus a $13.3 million Q2 2025 net loss, the $0.13 of Q2 2026 diluted EPS versus a $0.16 Q2 2025 diluted loss per share, the $54.9 million of cash as of June 30, 2026, the $25 million of net proceeds from the July 2026 equity financing, the proforma $80 million of cash, the company's reiterated full-year financial guidance, the three key TIDES US 2026 presentations demonstrating enzyme-driven stereoisomer control of siRNA, the superior performance of Codexis ligase in siRNA ligation reactions, and the improved sustainability metrics of the ECO Synthesis manufacturing platform compared to Solid-Phase Oligonucleotide Synthesis, the upcoming ECO GMP Manufacturing Center building permit application, the planned full production capability by the end of 2027, the goal of commencing an additional strategic CDMO partnership by the end of 2026, the goal of advancing drug innovator partnerships toward clinical stage manufacturing agreements, and the FDA Emerging Technologies team meeting in the fourth quarter of 2026 to discuss ECO Synthesis-derived siRNA product quality is the cleanest single read on what the ECO-Synthesis-pivot is producing. The strategic tension is the ECO Synthesis platform industrialization against the platform commercialization timing, and the forward question is whether the company can convert the TIDES US platform demonstration and the FDA Emerging Technologies meeting into the next leg of strategic CDMO partnerships and clinical stage manufacturing agreements.